{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:33:20Z","timestamp":1780065200957,"version":"3.54.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The phosphoinositide 3-kinase (PI3K) signaling pathway is an interesting target in cancer treatment. The awareness of the proarrhythmic risk of PI3K inhibitors was raised because PI3K is also involved in regulating signaling toward cardiac ion channels. Canine cardiomyocytes treated with PI3K inhibitors show an increased action potential duration and reduced cardiac repolarizing currents. Now, the potential proarrhythmic effect of chronic treatment of PI3K\/mTOR inhibitor GSK2126458 (omipalisib) was investigated in the atrioventricular (AV) block dog model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Purpose-bred Mongrel dogs received complete AV block by ablation of the bundle of His and their hearts were paced in the right ventricular apex at VDD-mode (RVA-VDD). In this way, sinus rhythm was maintained for 15 \u00b1 1 days and thereby bradycardia-induced cardiac remodeling was prevented. Dogs received 1 mg\/kg omipalisib once (<jats:italic>n<\/jats:italic> = 3) or twice (<jats:italic>n<\/jats:italic> = 10) a day <jats:italic>via<\/jats:italic> oral administration for 7 days. Under standardized conditions (anesthesia, bradycardia at 60 beats\/min, and a dofetilide challenge), potential proarrhythmic effects of omipalisib were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twice daily dosing of omipalisib increased accumulative plasma levels compared to once daily dosing accompanied with adverse events. Omipalisib prolonged the QT interval at baseline and more strongly after the dofetilide challenge (490 \u00b1 37 to 607 \u00b1 48 ms). The arrhythmic outcome after omipalisib resulted in single ectopic beats in 30% of dogs perpetuating in multiple ectopic beats and TdP arrhythmia in 20% of dogs. Isolated ventricular cardiomyocytes from omipalisib-treated dogs showed a diminished I<jats:sub>Ks<\/jats:sub> current density.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Chronic treatment of PI3K\/mTOR inhibitor omipalisib prolonged the QT interval in a preclinical model under standardized proarrhythmic conditions. Furthermore, this study showed that electrical remodeling induced by omipalisib had a mild proarrhythmic outcome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.956538","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T04:36:50Z","timestamp":1659501410000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["PI3K\/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model"],"prefix":"10.3389","volume":"9","author":[{"given":"J. J. A.","family":"van Bavel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. D. M.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J. C.","family":"Houtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bossu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. W.","family":"Sparidans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A. G.","family":"van der Heyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1242\/dev.137075","article-title":"Proliferation, survival and metabolism: the role of PI3K\/AKT\/mTOR signalling in pluripotency and cell fate determination","volume":"143","author":"Yu","year":"2016","journal-title":"Development."},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/82_2010_68","article-title":"Oncogenic mutations of PIK3CA in human cancers","volume":"347","author":"Samuels","year":"2010","journal-title":"Curr Top Microbiol Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.bbadis.2018.02.003","article-title":"PI3K\/AKT\/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis","volume":"1864","author":"Varshney","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.mcn.2018.08.004","article-title":"Neural progenitors derived from tuberous sclerosis complex patients exhibit attenuated PI3K\/AKT signaling and delayed neuronal differentiation","volume":"92","author":"Zucco","year":"2018","journal-title":"Mol Cell Neurosci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell."},{"key":"B7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat Rev Drug Discov."},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT pathway as a target for cancer treatment","volume":"67","author":"Mayer","year":"2016","journal-title":"Annu Rev Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms22073464","article-title":"PI3K inhibitors in cancer: clinical implications and adverse effects","volume":"22","author":"Mishra","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s12471-018-1148-7","article-title":"Cardio-oncology: an overview on outpatient management and future developments","volume":"26","author":"Teske","year":"2018","journal-title":"Neth Heart J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40169-020-0261-6","article-title":"PI3K inhibitors in thrombosis and cardiovascular disease","volume":"9","author":"Durrant","year":"2020","journal-title":"Clin Transl Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fphys.2018.00127","article-title":"Cardiac arrhythmias and antiarrhythmic drugs: an autophagic perspective","volume":"9","author":"Van Bavel","year":"2018","journal-title":"Front Physiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cardfail.2013.02.005","article-title":"PI3K inhibitors as novel cancer therapies: implications for cardiovascular medicine","volume":"19","author":"McLean","year":"2013","journal-title":"J Card Fail."},{"key":"B14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1161\/CIRCRESAHA.116.303975","article-title":"Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels","volume":"116","author":"Ballou","year":"2015","journal-title":"Circ Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.yjmcc.2012.07.004","article-title":"Exercise training and PI3Kalpha-induced electrical remodeling is independent of cellular hypertrophy and Akt signaling","volume":"53","author":"Yang","year":"2012","journal-title":"J Mol Cell Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"131ra50","DOI":"10.1126\/scitranslmed.3003623","article-title":"Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome","volume":"4","author":"Lu","year":"2012","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1021\/ml900028r","article-title":"Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin","volume":"1","author":"Knight","year":"2010","journal-title":"ACS Med Chem Lett."},{"key":"B18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.4161\/cbt.11.11.15527","article-title":"Comparison of the effects of the PI3K\/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells","volume":"11","author":"Leung","year":"2011","journal-title":"Cancer Biol Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12967-021-03050-7","article-title":"GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experiments","volume":"19","author":"Feng","year":"2021","journal-title":"J Transl Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e927106","DOI":"10.12659\/MSM.927106","article-title":"Omipalisib inhibits esophageal squamous cell carcinoma growth through inactivation of phosphoinositide 3-kinase (PI3K)\/AKT\/Mammalian target of rapamycin (mTOR) and ERK signaling","volume":"26","author":"Zhu","year":"2020","journal-title":"Med Sci Monit."},{"key":"B21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/thoraxjnl-2015-207429","article-title":"Exploration of a potent PI3 kinase\/mTOR inhibitor as a novel anti-fibrotic agent in IPF","volume":"71","author":"Mercer","year":"2016","journal-title":"Thorax."},{"key":"B22","doi-asserted-by":"publisher","first-page":"58504","DOI":"10.18632\/oncotarget.17215","article-title":"The dual PI3K\/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2(+\/-) mice through suppression of cell proliferation and induction of apoptosis","volume":"8","author":"Narov","year":"2017","journal-title":"Oncotarget."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1158\/1078-0432.CCR-15-1665","article-title":"First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies","volume":"22","author":"Munster","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10637-016-0377-0","article-title":"A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K\/mTOR inhibitor GSK2126458 in patients with advanced solid tumors","volume":"34","author":"Grilley-Olson","year":"2016","journal-title":"Invest New Drugs."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1801992","DOI":"10.1183\/13993003.01992-2018","article-title":"A randomised, placebo-controlled study of omipalisib (PI3K\/mTOR) in idiopathic pulmonary fibrosis","volume":"53","author":"Lukey","year":"2019","journal-title":"Eur Respir J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/bph.15436","article-title":"The canine chronic atrioventricular block model in cardiovascular preclinical drug research","volume":"179","author":"Loen","year":"2022","journal-title":"Br J Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.pharmthera.2008.03.006","article-title":"The canine model with chronic, complete atrio-ventricular block","volume":"119","author":"Oros","year":"2008","journal-title":"Pharmacol Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1161\/01.CIR.100.24.2455","article-title":"Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes","volume":"100","author":"Volders","year":"1999","journal-title":"Circulation."},{"key":"B29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0008-6363(02)00717-4","article-title":"Coordinated down-regulation of KCNQ1 and KCNE1 expression contributes to reduction of I(Ks) in canine hypertrophied hearts","volume":"57","author":"Ramakers","year":"2003","journal-title":"Cardiovasc Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","article-title":"An improved method to correct the QT interval of the electrocardiogram for changes in heart rate","volume":"22","author":"Van de Water","year":"1989","journal-title":"J Pharmacol Methods."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1161\/01.CIR.0000145162.64183.C8","article-title":"Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs","volume":"110","author":"Thomsen","year":"2004","journal-title":"Circulation."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/j.1476-5381.2010.00934.x","article-title":"The Electro-Mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias","volume":"161","author":"Van der Linde","year":"2010","journal-title":"Br J Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.hrthm.2013.09.027","article-title":"Novel parameters to improve quantification of repolarization reserve and arrhythmogenesis using a dofetilide challenge","volume":"10","author":"Stams","year":"2013","journal-title":"Heart Rhythm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.15420\/aer.2019.16.2","article-title":"The increment of short-term variability of repolarisation determines the severity of the imminent arrhythmic outcome","volume":"8","author":"Smoczynska","year":"2019","journal-title":"Arrhythm Electrophysiol Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jpba.2015.01.026","article-title":"Liquid chromatography-tandem mass spectrometric assay for the PI3K\/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate","volume":"107","author":"Dolman","year":"2015","journal-title":"J Pharm Biomed Anal."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1111\/bph.14217","article-title":"Selective late sodium current inhibitor GS-458967 suppresses Torsades de Pointes by mostly affecting perpetuation but not initiation of the arrhythmia","volume":"175","author":"Bossu","year":"2018","journal-title":"Br J Pharmacol."},{"key":"B37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/978-1-4471-4881-4_23","article-title":"Ventricular electrical remodeling in compensated cardiac hypertrophy","volume-title":"Electrical Diseases of the Heart","author":"Bourgonje","year":"2013"},{"key":"B38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11897-018-0376-x","article-title":"Chronic right ventricular pacing in the heart failure population","volume":"15","author":"Gould","year":"2018","journal-title":"Curr Heart Fail Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e010972","DOI":"10.1161\/JAHA.118.010972","article-title":"His bundle pacing: a new strategy for physiological ventricular activation","volume":"8","author":"Lewis","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1161\/01.CIR.98.11.1125","article-title":"Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling","volume":"98","author":"Vos","year":"1998","journal-title":"Circulation."},{"key":"B41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1113\/jphysiol.2006.124222","article-title":"Window Ca2+ current and its modulation by Ca2+ release in hypertrophied cardiac myocytes from dogs with chronic atrioventricular block","volume":"579","author":"Antoons","year":"2007","journal-title":"J Physiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1161\/01.CIR.102.17.2145","article-title":"Contractile adaptations preserving cardiac output predispose the hypertrophied canine heart to delayed afterdepolarization-dependent ventricular arrhythmias","volume":"102","author":"De Groot","year":"2000","journal-title":"Circulation."},{"key":"B43","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1161\/CIRCULATIONAHA.109.873380","article-title":"Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction","volume":"120","author":"Lu","year":"2009","journal-title":"Circulation."},{"key":"B44","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1634\/theoncologist.2015-0248","article-title":"Hyperglycemia and phosphatidylinositol 3-kinase\/protein kinase B\/mammalian target of rapamycin (PI3K\/AKT\/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management","volume":"7","author":"Khan","year":"2016","journal-title":"Oncologist."},{"key":"B45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cardiores.2006.11.010","article-title":"Diabetes mellitus attenuates the repolarization reserve in mammalian heart","volume":"73","author":"Lengyel","year":"2007","journal-title":"Cardiovasc Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.hrthm.2012.05.016","article-title":"Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo","volume":"9","author":"Varkevisser","year":"2012","journal-title":"Heart Rhythm."},{"key":"B47","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/FJC.0000000000000488","article-title":"Short-term variability of repolarization is superior to other repolarization parameters in the evaluation of diverse antiarrhythmic interventions in the chronic atrioventricular block dog","volume":"69","author":"Bossu","year":"2017","journal-title":"J Cardiovasc Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/10837450902891485","article-title":"Gender and interindividual variability in pharmacokinetics","volume":"41","author":"Nicolas","year":"2009","journal-title":"Drug Metab Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1021\/acs.molpharmaceut.6b01118","article-title":"Analyzing the potential root causes of variability of pharmacokinetics in preclinical species","volume":"14","author":"Daublain","year":"2017","journal-title":"Mol Pharm."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.956538\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T04:36:55Z","timestamp":1659501415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.956538\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":49,"alternative-id":["10.3389\/fcvm.2022.956538"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.956538","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"article-number":"956538"}}